- Home
- GHI vs VNDA Comparison
GHI vs VNDA Comparison
Compare GHI & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHI
- VNDA
- Stock Information
- Founded
- GHI 1998
- VNDA 2002
- Country
- GHI United States
- VNDA United States
- Employees
- GHI N/A
- VNDA N/A
- Industry
- GHI Finance: Consumer Services
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- GHI Finance
- VNDA Health Care
- Exchange
- GHI Nasdaq
- VNDA Nasdaq
- Market Cap
- GHI 254.1M
- VNDA 249.4M
- IPO Year
- GHI N/A
- VNDA 2006
- Fundamental
- Price
- GHI $8.30
- VNDA $4.38
- Analyst Decision
- GHI Strong Buy
- VNDA Strong Buy
- Analyst Count
- GHI 4
- VNDA 2
- Target Price
- GHI $14.88
- VNDA $15.50
- AVG Volume (30 Days)
- GHI 123.5K
- VNDA 687.6K
- Earning Date
- GHI 11-06-2025
- VNDA 10-29-2025
- Dividend Yield
- GHI 17.90%
- VNDA N/A
- EPS Growth
- GHI N/A
- VNDA N/A
- EPS
- GHI N/A
- VNDA N/A
- Revenue
- GHI $27,326,828.00
- VNDA $212,074,000.00
- Revenue This Year
- GHI $223.15
- VNDA $15.45
- Revenue Next Year
- GHI $5.11
- VNDA $37.82
- P/E Ratio
- GHI N/A
- VNDA N/A
- Revenue Growth
- GHI N/A
- VNDA 11.12
- 52 Week Low
- GHI $8.20
- VNDA $3.81
- 52 Week High
- GHI $13.29
- VNDA $5.70
- Technical
- Relative Strength Index (RSI)
- GHI 15.88
- VNDA 31.61
- Support Level
- GHI $8.20
- VNDA $5.46
- Resistance Level
- GHI $8.72
- VNDA $5.70
- Average True Range (ATR)
- GHI 0.27
- VNDA 0.25
- MACD
- GHI -0.07
- VNDA -0.15
- Stochastic Oscillator
- GHI 5.26
- VNDA 7.69
About GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.